Phospholipase A2 group VI (PLA2G6), also known as calcium-independent phospholipase A2 (iPLA2-VIA), is an 84 kDa enzyme belonging to the phospholipase A2 superfamily that catalyzes the hydrolysis of the sn-2 fatty acid from phospholipids, generating free fatty acids and lysophospholipids. Unlike cytosolic PLA2 enzymes that require calcium for activity, PLA2G6 functions independently of calcium, making it uniquely suited for its primary localization to mitochondria where it plays critical roles in membrane lipid remodeling, mitochondrial function, and cellular signaling.
The importance of PLA2G6 in neurodegenerative diseases has become increasingly clear through the identification of disease-causing mutations that lead to infantile neuroaxonal dystrophy (INAD), a severe pediatric neurodegenerative disorder, and atypical parkinsonism (PARK14), a late-onset movement disorder. These conditions are classified within the broader spectrum of neurodegeneration with brain iron accumulation (NBIA) disorders, highlighting the critical role of PLA2G6 in maintaining iron homeostasis and neuronal survival[1].
Phospholipases A2 represent a diverse family of enzymes that cleave fatty acids from phospholipids, producing bioactive lipid mediators that serve as signaling molecules, membrane components, and precursors for inflammatory cascades. PLA2G6 is distinguished by its calcium-independent mechanism and mitochondrial localization, positioning it at the intersection of lipid metabolism, mitochondrial biology, and neuroprotection[2].
The discovery of PLA2G6 mutations as the causative factor in infantile neuroaxonal dystrophy in 2006 marked a turning point in understanding this rare but devastating disorder. Subsequent research has revealed that PLA2G6 dysfunction contributes not only to early-onset neurodegeneration but also to adult-onset Parkinson's disease, demonstrating the protein's importance across the lifespan[3].
Beyond genetic disorders, PLA2G6 has been implicated in Alzheimer's disease, Huntington's disease, and various models of neuroinflammation. The enzyme's broad substrate specificity and central position in lipid metabolism make it a potential therapeutic target for multiple neurodegenerative conditions[4].
PLA2G6 is a large enzyme with a molecular weight of approximately 84.7 kDa, encoded by the PLA2G6 gene located on chromosome 22q13.1. The protein contains several distinct structural domains that confer its unique enzymatic properties and cellular localization[5]:
The catalytic domain contains the characteristic catalytic triad of lipases (Ser, Asp, His) and displays specificity for the sn-2 position of phospholipids. Unlike cytosolic PLA2 (cPLA2) enzymes that require submicromolar calcium concentrations for activation, PLA2G6 maintains full activity in calcium-free conditions, a property conferred by structural features that stabilize the active site conformation independently of calcium binding[6].
PLA2G6 catalyzes phospholipid hydrolysis through a serine-dependent mechanism:
The enzyme shows broad substrate specificity, hydrolyzing phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol. This versatility allows PLA2G6 to participate in diverse membrane remodeling processes[7].
PLA2G6 exhibits predominant mitochondrial localization, with the enzyme associated with the inner mitochondrial membrane. This localization is mediated by:
Additional pools of PLA2G6 are found in the cytosol and associated with the endoplasmic reticulum, where the enzyme participates in general membrane lipid metabolism and quality control[8].
PLA2G6 plays a central role in maintaining mitochondrial membrane composition and integrity[9]:
The products of PLA2G6 activity serve as important signaling molecules[10]:
Recent research has revealed a crucial role for PLA2G6 in cellular iron homeostasis[11]:
This link between PLA2G6 and iron metabolism explains the iron accumulation phenotype observed in PLA2G6-related disorders.
PLA2G6 exhibits neuroprotective properties through multiple mechanisms[12]:
INAD is a rare autosomal recessive neurodegenerative disorder characterized by progressive loss of axons, with onset typically occurring in the first two years of life. PLA2G6 mutations account for the majority of INAD cases[13][14]:
Clinical Features:
Pathogenesis:
PLA2G6 deficiency leads to:
Genetics:
Over 50 pathogenic mutations in PLA2G6 have been identified, including:
PARK14 represents a spectrum of adult-onset movement disorders caused by PLA2G6 mutations[15][16]:
Clinical Features:
Pathogenesis:
Similar mechanisms to INAD but with later onset, suggesting:
PLA2G6 is implicated in Alzheimer's disease pathophysiology through several mechanisms[17][18]:
Amyloid Metabolism:
Tau Pathology:
Neuroinflammation:
While PLA2G6 mutations cause atypical parkinsonism (PARK14), the enzyme is also implicated in idiopathic Parkinson's disease[19]:
PLA2G6 contributes to Huntington's disease pathogenesis through[20]:
The PLA2G6 gene (also known as iPLA2-VIA) spans approximately 36 kb on chromosome 22q13.1 and contains 33 exons encoding the 753-amino acid protein[21].
Gene Structure:
| Mutation Type | Phenotype | Mechanism |
|---|---|---|
| Severe loss-of-function | INAD (infantile) | Complete enzyme loss |
| Partial loss-of-function | INAD (atypical/late-onset) | Residual activity |
| Missense with some activity | PARK14 (adult-onset) | Partial function retained |
| Compound heterozygous | Variable | Mixed severity |
Given the mitochondrial dysfunction and oxidative stress in PLA2G6-related disorders, several therapeutic strategies are being explored[22][23]:
Coenzyme Q10:
Vitamin E:
Mitochondrial supplements:
Gene replacement approaches are in development:
Pharmaceutical approaches to activate residual PLA2G6:
Compensating for altered phospholipid metabolism:
Several animal models have been developed to study PLA2G6 function[24]:
PLA2G6 and its lipid products show biomarker potential[25]:
PLA2G6 mutations cause infantile neuroaxonal dystrophy. American Journal of Human Genetics. 2006. ↩︎
Phospholipase A2 in cellular signaling and inflammation. Cellular and Molecular Biology. 2005. ↩︎
Clinical features of PLA2G6-related neurodegeneration. Brain. 2011. ↩︎
iPLA2 in Alzheimer's disease. Neurobiology of Aging. 2011. ↩︎
Structure of the ankyrin repeat domain of iPLA2. Journal of Biological Chemistry. 2003. ↩︎
Catalytic mechanism of iPLA2. Biochemistry. 2002. ↩︎
Substrate specificity of iPLA2-VIA. Journal of Biological Chemistry. 2000. ↩︎
Mitochondrial localization of iPLA2. Journal of Biological Chemistry. 2006. ↩︎
iPLA2 and mitochondrial function. Cell Calcium. 2009. ↩︎
Lysophospholipid signaling in the nervous system. Neurochemical Research. 2004. ↩︎
iPLA2 and iron metabolism. Cellular and Molecular Neurobiology. 2013. ↩︎
Neuroprotective functions of iPLA2. Journal of Neurochemistry. 2010. ↩︎
INAD: clinical features and genetics. Brain. 2011. ↩︎
Neuropathology of INAD. Acta Neuropathologica. 2006. ↩︎
PARK14: atypical parkinsonism caused by PLA2G6. Brain. 2012. ↩︎
Adult-onset PLA2G6-related neurodegeneration. Movement Disorders. 2014. ↩︎
iPLA2 and amyloid metabolism. Journal of Alzheimer's Disease. 2013. ↩︎
Phospholipases in Alzheimer's disease. Biochimica et Biophysica Acta. 2015. ↩︎
iPLA2 in Parkinson's disease models. Journal of Neuroscience Research. 2016. ↩︎
iPLA2 in Huntington's disease. Journal of Neurochemistry. 2016. ↩︎
PLA2G6 gene structure. Genomics. 1998. ↩︎
Therapeutic approaches to INAD. Molecular Genetics and Metabolism. 2015. ↩︎
Coenzyme Q10 in NBIA disorders. Molecular Genetics and Metabolism. 2013. ↩︎
iPLA2 knockout mice. Proceedings of the National Academy of Sciences. 2003. ↩︎
Biomarkers in NBIA disorders. Molecular Genetics and Metabolism. 2017. ↩︎